Biomm S.A.

São Paulo Stock Exchange BIOM3.SA

Biomm S.A. Operating Income Margin for the year ending December 31, 2023: -61.36%

Biomm S.A. Operating Income Margin is -61.36% for the year ending December 31, 2023, a 18.39% change year over year. Operating Income Ratio is the proportion of a company's operating income to its net sales, measuring the efficiency of its core business operations in generating profits.

Biomm S.A. Operating Income Margin for the year ending December 31, 2022 was -75.19%, a -23.15% change year over year.
Biomm S.A. Operating Income Margin for the year ending December 31, 2021 was -61.06%, a 39.44% change year over year.
Biomm S.A. Operating Income Margin for the year ending December 31, 2020 was -100.81%, a 79.99% change year over year.
Biomm S.A. Operating Income Margin for the year ending December 31, 2019 was -503.73%, a 78.49% change year over year.

Key data

Date	Operating Income Margin	EBT Margin	Net Income Margin	EBITDA Margin

São Paulo Stock Exchange: BIOM3.SA

Biomm S.A.

CEO	Mr. Heraldo Carvalho Marchezini
IPO Date	Jan. 11, 2000
Location	Brazil
Headquarters	Rua dos Pinheiros, 610
Employees	130
Sector	Healthcare
Industries Pharmaceuticals 3D Printing Biotechnology Cosmetics Drugstores & Retail Pharmacies Eyewear Personal Care Pet Food

Description

Biomm S.A. operates as a biotechnology company in Brazil. It offers AFREZZA, a human insulin inhalation powder; CONFORT CARE, a moisturizing foot cream; GLARGILIN, a glargine insulin; and HERZUMA, a trastuzumab. Biomm S.A. was founded in 2001 and is based in São Paulo, Brazil.

Key trends

Past 5 years